Evogene reaches board deal: what it means for Evogene stock

Published on 10/14/2026 at 06:15 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

The pact sets seven directors and a 60-day standstill. Evogene stock stood at USD 0.39 on October 13, 2026 versus USD 1.00 Nasdaq minimum.

Board changes and listing deadline

Evogene reached a cooperation agreement with Pure Capital Group on October 6, 2026.
The planned board will have seven directors, including four Pure Capital nominees.
Evogene stock last traded at USD 0.39 on Nasdaq on October 13, 2026.
Evogene has until March 29, 2027, to regain Nasdaq minimum bid compliance.

EVGN, IL0011050551, Illustration mit AI erstellt.

Evogene (ISIN IL0011050551) agreed with Pure Capital Group on October 6, 2026, to resolve shareholder disputes and reconstitute its board. The agreement provides for a seven-member board, including four Pure Capital nominees, while a 60-day standstill limits new share and convertible-security issuance, according to PR Newswire.

Three events shaped the stock

On May 16, 2026, Evogene reported quarterly earnings per share of minus USD 0.60 and revenue of USD 0.33 million, missing consensus earnings per share of minus USD 0.27 and revenue expectations of USD 0.35 million, according to MarketBeat.

On September 30, 2026, Nasdaq granted Evogene an additional 180-day period to restore compliance with its USD 1.00 minimum bid requirement. The company must hold a closing bid of at least USD 1.00 for 10 consecutive business days, according to Fidelity.

On October 6, 2026, the board agreement added a governance timetable to that listing issue: shareholders are expected to vote within 42 days of execution, and the four Pure Capital nominees would join three continuing directors. The standstill also restricts ordinary-course issuance outside employee compensation.

What does the deal change?

The agreement removes a contested shareholder process while concentrating the near-term test on execution and Nasdaq compliance. A seven-seat board with four nominees from Pure Capital gives the investor group a majority after shareholder approval, while the 60-day issuance restriction narrows one financing route during the transition.

Nasdaq deadline remains March 2027

Evogene has until March 29, 2027, to regain the minimum bid requirement. The last Nasdaq price was USD 0.39 on October 13, 2026, against the USD 1.00 threshold, while the 52-week range was USD 0.35 to USD 1.49 and market capitalization was USD 3.4 million.

MarketBeat lists November 19, 2026, as the estimated next earnings date and identifies Evogene as a Nasdaq-listed healthcare biotechnology company. The company reported second-quarter 2026 revenue of USD 0.35 million and a net loss of USD 1.59 million in the financial data for the period ended June 30, 2026.

Price and listing test

Evogene was last at USD 0.39 on Nasdaq on October 13, 2026. The listing test remains defined by the USD 1.00 minimum bid and the March 29, 2027, deadline, rather than by the board agreement alone.